Mumbai: The dispute between the Hiremath and Kalyani families over the control of Mumbai-based Hikal has taken a twist. The Kalyani Group, owners of Baba Kalyani-led Bharat Forge, in an affidavit filed in the Bombay High Court claimed that the 'family arrangement' on the stake transfer in the chemical and life sciences company was a 'note' by Baba Kalyani's father, Neelkanth Kalyani, and is not sustainable before law
Supriya Lifescience gets reality check; Hikal back in demand after 11 sessions
Shares of pharmaceutical companies came under pressure in Friday's session, falling by up to 6 per cent on the BSE.
Hikal Ltd., a preferred long-term partner for leading global life sciences companies, posted 236% rise in net profit at Rs. 51 crore for the first quarter ended June 30, 2021.
Life sciences NSE -0.27 % firm Hikal Ltd NSE -4.91 % on Wednesday said it has signed a 10-year deal with a global pharmaceutical company for development and supply of a portfolio of niche Active Pharmaceutical Ingredients (APIs).nnnRead more at:nLife sciences NSE -0.27 % firm Hikal Ltd NSE -4.91 % on Wednesday said it has signed a 10-year deal with a global pharmaceutical company for development and supply of a portfolio of niche Active Pharmaceutical Ingredients (APIs)
Shares of pharmaceutical companies were on a roll at the bourses on Friday, with the S&P BSE Healthcare index surging nearly 3 per cent to hit its record high on the back of positive news flow.
Hikal develops Favipiravir API, its intermediates
Shares of Hikal were locked in the upper circuit band of 5 per cent at Rs 115 on the BSE on Friday after the company announced the successful development of Favipiravir active pharmaceutical ingredient (API) and its intermediates. The drug is in various stages of clinical trials in many countries as an experimental treatment of Covid-19.
Hikal Ltd. has announced a donation of Rs 1 crore to the PM Cares Fund to aid the government’s initiatives towards combating and overcoming the spread of the deadly Coronavirus in India.
Hikal Limited has informed the bourses that the company has received a permission from the government authorities to restart its operations since it is a provider of the essential services (pharmaceutical and continuous industries), which are exempted from the lockdown.